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M.A. Luque-Fernandez et al. / European Journal of Cancer 129 (2020) 4e14 5comorbidity status at 6 months and 1 year. We used a flexible parametric model to derive the
excess mortality hazard ratios (HRs) for multimorbidity after adjusting for sex, age at diag-
nosis, cancer stage and treatment. We estimated the adjusted cumulative incidence of death
by comorbidity status and identified multimorbidity patterns.
Results: Among the study participants, 1,048 cases were diagnosed with cancers of the colon
and rectum, 2 cases with cancer of the anus with overlapping sites of the rectum and 11 cases
with anal adenocarcinomas but treated as colorectal cancer patients. Among 1,061 colorectal
cancer patients, 171 (16.2%) died before 6 months, 246 (23.3%) died before the 1-year follow-
up, and 324 (30.5%) had multimorbidity. Patients with multimorbidity had two times higher
mortality risk than those without comorbidities at 6 months (adjusted HR: 2.04; 95% confi-
dence interval [CI]: 1.30e3.20, p Z 0.002). The most frequent multimorbidity pattern was
conges t ive heart fa i lure þ diabetes . However , pat ients with rheumatolog ic
disease þ diabetes had two times higher 1-year mortality risk than those without comorbidities
(HR: 2.23; 95% CI: 1.23e4.07, p Z 0.008).
Conclusions: Multimorbidity was a strong independent predictor of short-term mortality at 6
months and 1 year among the colorectal cancer patients in Spain. The identified multimorbid-
ity pattern was consistent. Our findings might help identify patients at a higher risk for poor
cancer and treatment outcomes.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2018, there were 9.6 million deaths from cancer
worldwide, making cancer the second cause of death
globally [1]. In Spain, colorectal cancer (CRC) is the
most commonly diagnosed cancer, especially among the
elderly [2]. The rise in chronic non-communicable dis-
eases such as cancer, heart disease and diabetes reflects
lifestyle and diet changes and ageing. In Western
countries, the rapidly increasing costs of managing non-
communicable diseases including cancer have affected
economic growth [3]. Cancer incidence is expected to
accelerate in the coming decades in Europe, largely
because of global ageing. However, older people are
under-represented in clinical trials, mainly due to the
higher multimorbidity prevalence among this group [4].
Comorbidity refers to the presence of a long-term
health condition or disorder concomitant with a primary
disease such as cancer [5], while multimorbidity refers to
the existence of two or more comorbid conditions [6]. In
the elderly, comorbidity and multimorbidity are
increasingly perceived as a health issue [7,8]. Evidence
shows that comorbidities might influence cancer treat-
ment options, outcomes and overall survival [9,10].
We hypothesised that multimorbidity could be asso-
ciated with a higher mortality risk 6 months and 1 year
after a CRC diagnosis. However, evidence on the asso-
ciation of multimorbidity with short-term CRC survival
is limited [11,12]. Therefore, we aimed to assess the as-
sociation between multimorbidity and short-term mor-
tality and describe the most frequent patterns of
multimorbidity associated with a higher short-term
mortality risk among CRC patients in Spain.2. Materials and methods
2.1. Study design, participants, data and setting
This population-based cohort study included patients
diagnosed with CRC in 2011 in Girona and Granada,
Spain. The diagnoses were based on codes C18eC21
according to the International Classification of Diseases
for Oncology, 3rd Edition. The entry date of each pa-
tient into the cohort was defined as the date of cancer
diagnosis, and their exit date was defined as the date of
death or the date at 6 months or 1 year after their cancer
diagnosis, whichever occurred first.
Data were obtained retrospectively from two Spanish
population-based cancer registries and patients’ elec-
tronic health records. The data collection followed a
detailed protocol from the European High-Resolution
studies collaboration (TRANSCAN-HIGHCARE
project within the ERA-Net) [13]. We recorded infor-
mation on cancer stage at diagnosis (TNM staging
system, 7th edition), comorbidities, sex, type of surgery,
chemotherapy and vital status. Vital status for all CRC
patients was assessed at 6 months and 1 year after
cancer diagnosis and was ascertained based on infor-
mation from clinical records linked to the national death
registry of the Spanish National Statistics Institute
(INE).
Comorbidities were assessed from the electronic
health records based on codes from the International
Classification of Diseases, 10th Revision
(Supplementary Table S1). All recorded comorbidities
were included except for those comorbidities diagnosed
within 6 months before of cancer diagnosis that were
M.A. Luque-Fernandez et al. / European Journal of Cancer 129 (2020) 4e146excluded to prevent including CRC-related comorbid-
ities [14].
The study protocol was approved by the internal re-
view board of the Andalusian School of Public Health
(CP17/00206) and the ethics committee of the Depart-
ment of Health of the Andalusian Regional Government
(study 0072-N-18).
2.2. Variables related to patient characteristics
The main outcome of the study was short-term overall
mortality at 6 months and 1 year after cancer diagnosis
and the main exposure was multimorbidity. Age, sex,
type of surgery, chemotherapy and cancer stage were
also included in the study as confounders.
Age at diagnosis was categorised into <55, 55e64,
65e74 and 75 years. Comorbidities were classified
based on the Royal College of Surgeons (RCS) score, a
modified version of the Charlson’s comorbidity score,
which reduces the number of comorbidities to 12,
removes a category (peptic ulcer disease) and groups
diseases together (e.g. diabetes mellitus codes with or
without complications are grouped into a single cate-
gory). The score does not assign weights to individual
comorbidities [15]. The final score simply counts the
total number of comorbidities for each patient as no
comorbidities, one comorbidity and two or more
comorbidities, with two or more comorbidities defined
as multimorbidity [15]. The type of surgery was cat-
egorised as no receiving surgery, minor and major sur-
gery, based on the Classification of Interventions and
Procedures (fourth version, ‘OPCS-4’) (Supplementary
Table S2). Chemotherapy was categorized as neo-
adjuvant, adjuvant, palliative and not receiving it. The
final cancer-stage variable was defined as the combina-
tion of clinical and pathological TNM stages and cat-
egorised into four groups based on the TNM manual,
7th edition (AJCC staging system).
2.3. Statistical analysis
We described the study population and computed the
unadjusted mortality rates per 100 person-years and
unadjusted mortality rate ratios with 95% confidence
intervals (CIs). We estimated non-parametrically the
cumulative incidence of death at 6 months and 1 year
according to comorbidity status using the
NelsoneAalen estimator and log-rank test [16].
We used a flexible parametric modelling approach
consisting of restricted cubic spline-based hazard models
with three knots [17] to derive multivariable excess
mortality hazard ratios (HRs) and 95% CIs for multi-
morbidity after adjusting for age at diagnosis, sex,
cancer stage and treatment and using as reference the
category at lower risk. Due to data sparsity, chemo-
therapy and type of surgery were dichotomized as yes,
for patients receiving it, and no for those patients whodid not receive it. To account for the non-
proportionality effect of multimorbidity, we included
the interaction between the restricted cubic splines of
time and the multimorbidity variable. From the final
full-adjusted model we then derived the cumulative in-
cidences of death by comorbidity status (i.e. no
comorbidities, one comorbidity and two or more
comorbidities) that were standardised to the empirical
distribution of age, sex, cancer stage and treatment
[18,19].
Finally, we described the 10 most frequent patterns of
multimorbidity, derived the adjusted excess mortality
HRs comparing each multimorbidity pattern with no
comorbidity or any other different pattern with respect
to the total sample and plotted the 1-year cumulative
incidence of death for each multimorbidity pattern
adjusted for age, sex, cancer stage and treatment.
In sensitivity analysis, we restricted the analysis to
only those patients with tumour stage IeIII receiving
surgery plus tumour stage IV patients, we tested the
interaction between comorbidities with patients’ age and
tumour stage on cancer outcomes and estimated the
linear multiplicative combined effect of multimorbidity
with tumour stage and patients’ age at 1 year after
diagnosis.
We used Stata v.15.1 (StataCorp, College Station,
Texas, U.S.) including the user-written programs stpm2
v.1.7 and stpm2_standsurv v.1.1.1 for statistical analysis
and provide the Stata code used to run the analysis as a
supplementary file.3. Results
Among the study participants, 1,048 cases were diag-
nosed with cancers of the colon and rectum, 2 cases
with cancer of the anus with overlapping sites of the
rectum and 11 cases with anal adenocarcinomas but
treated as CRC patients. Among 1,061 CRC patients,
171 (16.1%) died before 6 months and 246 (23.2%) died
before the 1-year follow-up. The overall mortality rates
were 36.2/472.6 and 27.4/897.2 person-years at 6
months and 1 year, respectively. Table 1 shows the
patients’ vital status, age, sex, cancer stage, type of
surgery and chemotherapy by comorbidity status.
Older CRC patients (75 years) showed a higher
multimorbidity prevalence than younger CRC patients
(<55 years) (43.7% vs. 8.5%). Male CRC patients also
showed a higher multimorbidity prevalence than fe-
male patients (34.0% vs. 27.0%). Furthermore, CRC
patients who died before 1 year had approximately two
times higher prevalence of multimorbidity than those
who were alive at 1 year (45.2% vs. 27.0%) and at 6
months (49.1% vs. 27.8%). However, no significant
association was found between comorbidity status and
cancer stage. Patients who did not receive surgery and
chemotherapy had approximately two times higher
Table 1
Vital status, age, sex, cancer stage and cancer treatment according to the comorbidity status among colorectal cancer patients in Spain in 2011
(n Z 1,061, 171 deaths at 6 months and 246 deaths at 1 year).
Variable No comorbidity One comorbidity Two or more: multimorbidity p-value
N (%) N (%) N (%)
Vital status at 6 months <0.001
Alive 377 (43.2%) 253 (29.0%) 243 (27.8%)
Dead 36 (21.8%) 48 (29.1%) 81 (49.1%)
Vital status at 1 year <0.001
Alive 349 (43.7%) 234 (29.3%) 216 (27.0%)
Dead 64 (26.8%) 67 (28.0%) 108 (45.2%)
Age at diagnosis, years <0.001
<55 94 (72.3%) 25 (19.2%) 11 (8.5%)
55e64 118 (54.6%) 63 (29.2%) 35 (16.2%)
65e74 94 (34.9%) 82 (30.5%) 93 (34.6%)
75 107 (25.3%) 131 (31.0%) 185 (43.7%)
Sex 0.019
Male 232 (37.0%) 183 (29.0%) 215 (34.0%)
Female 181 (44.0%) 118 (29.0%) 109 (27.0%)
TNM stage 0.163
I 74 (44.3%) 46 (27.5%) 47 (28.1%)
II 92 (33.3%) 85 (30.8%) 99 (35.9%)
III 115 (40.8%) 76 (27.2%) 89 (31.9%)
IV 108 (40.7%) 85 (32.1%) 72 (27.2%)
Type of surgery 0.004
No surgery 49 (28.7%) 49 (28.7%) 73 (42.6%)
Minor surgery 21 (48.8%) 11 (25.6%) 11 (25.6%)
Major surgery 331 (41.3%) 235 (29.3%) 235 (29.3%)
Chemotherapy <0.001
Neoadjuvant 64 (50.8%) 36 (28.6%) 26 (20.6%)
Adjuvant 126 (47.9%) 79 (30.0%) 58 (22.0%)
Palliative 43 (44.3%) 31 (32.0%) 23 (23.7%)
Not received 176 (32.3%) 153 (28.1%) 215 (39.5%)
Missing values: TNM stage, n(%) Z 60(5.6%), comorbidities, n(%) Z 23(2.2%), type of surgery, n(%) Z 27(2.4%) and chemotherapy,
n(%) Z 22(2.0%).
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major surgery (i.e. 42.6% vs. 29.3%). Similarly, patients
who did not receive chemotherapy had approximately
two times higher prevalence of multimorbidity than
those who received any other type of chemotherapy
(i.e. 39.5% vs. 23.7%, 22.0% and 20.6% for palliative,
adjuvant and neoadjuvant chemotherapy, respectively)
(Table 1).
Table 2 shows the short-term overall mortality rates
by age, sex, cancer stage, type of surgery, chemotherapy
and comorbidity status. Compared with other age
groups, older patients (75 years) showed the highest
mortality rate. For instance, the 1-year mortality rate of
CRC patients aged 75 years was 47.5/100 person-
years, twice as high as that of patients aged 65e74
years (25.1/100 person-years).
CRC patients who did not receive surgery and those
with stage IV disease showed the highest mortality rates
with 127.1/100 and 74.4/100 person-years at 1 year,
respectively. Overall, CRC patients with multimorbidity
showed higher mortality rates at 6 months and 1 year
than those with one comorbidity or none. The mortality
rate ratios showed a higher risk for men, those who werediagnosed at an age of 75 years, those diagnosed at a
stage IV, those non-treated and those with multi-
morbidity (Table 2).
Table 3 shows the adjusted excess mortality HRs for
comorbidity and multimorbidity at 6 months and 1 year.
Overall, CRC patients with multimorbidity had
approximately two times higher excess short-term mor-
tality risk than those without comorbidities (adjusted
model 4, Table 3: HR at 6 months, 2.04; 95% CI,
1.30e3.32 and at 1 year, 1.54; 95% CI, 1.08e2.20), but
after multivariable adjustment for age, sex, cancer stage
and treatment, no significant association between one
comorbidity and mortality at 1 year was found. Like-
wise, the 75-year group had higher excess mortality
than the <55e64-year group only at 1 year after diag-
nosis (adjusted model 4, Table 3: HR at 6 months, 1.89;
95% CI, 0.83e4.27 and at 1 year, 1.88; 95% CI,
1.06e3.33), patients with stage IV CRC at diagnosis had
thirteen times higher short-term excess mortality at 1
year than those with stage I (adjusted model 4, Table 3:
HR, 13.20; 95% CI, 6.70e26.00). Non-treated patients
(i.e. surgery or chemotherapy) had three and four times
higher short-term mortality risk at 1 year than those
Table 2
Six-month (A) and one-year (B) mortality rates by sex, age, cancer stage, treatment and comorbidity status among colorectal cancer patients in
Spain in 2011 (n Z 1,061, 171 deaths at 6 months and 246 deaths at 1 year).
Deaths per person-years Mortality rate Mortality rate ratio 95% CI p-value
Six-month mortality (A)
Sex
Male 105/288.53 36.39 Ref.
Female 66/184.10 35.85 0.99 0.72e1.34 0.924
Age at diagnosis, years
<55 5/63.34 7.89 Ref.
55e64 9/106.64 8.44 1.07 0.35e3.19 0.900
65e74 43/123.56 34.80 4.41 1.75e11.13 <0.001
75 114/179.09 63.66 8.06 3.29e19.75 <0.001
TNM stage
I 5/82.61 6.05 Ref.
II 41/125.83 32.58 5.38 2.13e13.62 <0.001
III 22/135.69 16.21 2.68 1.01e7.07 0.038
IV 89/105.76 84.15 13.90 5.65e34.23 <0.001
Type of surgery
No surgery 89/57.79 153.99 Ref.
Minor surgery 3/20.79 14.42 0.09 0.03e0.30 <0.001
Major surgery 70/385.34 18.16 0.12 0.09e0.16 <0.001
Chemotherapy
Neoadjuvant 4/62.05 6.45 Ref.
Adjuvant 2/131.59 1.52 0.23 0.43e1.29 0.069
Palliative 19/44.65 42.55 6.60 2.25e19.40 <0.001
Not received 142/226.44 67.71 9.73 3.60e26.28 <0.001
Comorbidity status
No comorbidity 36/195.17 18.45 Ref.
One comorbidity 48/135.26 35.49 1.92 1.25e2.96 0.003
Multimorbidity 81/134.45 60.24 3.27 2.21e4.84 <0.001
One-year mortality (B)
Sex
Male 157/545.02 28.81 Ref.
Female 89/352.16 25.27 0.97 0.68e1.14 0.324
Age at diagnosis, years
<55 13/124.23 10.46 Ref.
55e64 18/209.57 8.59 0.82 0.40e1.68 0.587
65e74 59/234.76 25.13 2.40 1.32e4.38 0.003
75 156/328.61 47.47 4.54 2.58e7.99 <0.001
TNM stage
I 11/162.57 6.77 Ref.
II 46/244.73 18.80 2.78 1.44e5.36 0.002
III 32/264.87 12.08 1.79 0.90e3.54 0.093
IV 136/182.88 74.37 15.5 5.95e20.32 <0.001
Type of surgery
No surgery 118/92.86 127.07 Ref.
Minor surgery 5/40.46 12.36 0.10 0.04e0.24 <0.001
Major surgery 108/749.62 14.41 0.11 0.09e0.15 <0.001
Chemotherapy
Neoadjuvant 12/120.68 9.94 Ref.
Adjuvant 15/259.99 5.77 0.58 0.27e1.24 0.155
Palliative 39/78.45 49.72 5.00 2.62e9.55 <0.001
Not received 175/423.29 41.34 4.16 2.32e7.46 <0.001
Comorbidity status
No comorbidity 64/376.42 17.00 Ref.
One comorbidity 67/257.32 26.04 1.53 1.08e2.16 0.014
Multimorbidity 108/249.34 43.31 2.55 1.87e3.47 <0.001
CI: confidence interval.
Missing values: TNM stage, n(%) Z 60(5.6%), comorbidities, n(%) Z 23(2.2%), type of surgery, n(%) Z 27(2.4%) and chemotherapy,
n(%) Z 22(2.0%).
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year for no receiving surgery, 3.10; 95% CI, 2.14e4.48
and, 4.53; 95% CI, 3.13e6.54 for those patients who didnot receive chemotherapy). However, no significant as-
sociation was found between short-term mortality and
sex.
Table 3
Short-term excess mortality hazard ratios for comorbidity and multimorbidity adjusted for sex, age, cancer stage and treatment among colorectal
cancer patients in Spain in 2011 (n Z 1,061, 171 deaths at 6 months and 246 deaths at 1 year).
Variable Deaths (%) Model 1 HR (95% CI) Model 2 HR (95% CI) Model 3 HR (95% CI) Model 4 HR (95% CI)
6 m 1yr 6 m 1yr 6 m 1yr 6 m 1yr 6 m 1yr
Comorbidity status
No comorbidity 3 (8.7) 64
(15.5)
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HR, hazard ratio; CI, confidence interval.
Model 1, adjusted for sex and age; Model 2, adjusted for sex, age and TNM stage; Model 3, adjusted for sex, age, TNM stage and type of surgery;
Model 4, adjusted for sex, age, TNM stage, type of surgery and chemotherapy. Missing values: TNM stage, n(%) Z 60(5.6%), comorbidities,
n(%) Z 23(2.2%), type of surgery, n(%) Z 27(2.4%) and chemotherapy, n(%) Z 22(2.0%).
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death at 6 months and 1 year by comorbidity status.
CRC patients with multimorbidity showed a consis-
tently higher cumulative incidence of death at 6 months
and 1 year after cancer diagnosis than those with no
comorbidity (log-rank test p < 0.001) (Fig. 1).
Furthermore, we found a significant increasing trend of
cumulative incidence by comorbidity status (test for
trend p < 0.001).
Fig. 2 shows the cumulative incidences of death
standardised to the empirical distribution of age, sex
and cancer stage. CRC patients with multimorbidity had
a consistently higher cumulative incidence than thosewith one or no comorbidities at 6 months and 1 year.
The differences were markedly higher at 6 months than
at 1 year, and there was no significant difference in cu-
mulative incidence between those with one comorbidity
and those without comorbidities at either 6 months or 1
year (Fig. 2).
Supplementary Table S3 shows the multimorbidity
prevalence and 10 most frequent multimorbidity pat-
terns. A total of 324 patients (31.2%) had multi-
morbidity. The most frequent pattern was congestive
heart failure (CHF) þ diabetes (5.8%), followed by
CHF þ chronic obstructive pulmonary disease (COPD)
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Fig. 1. Unadjusted short-term cumulative incidences of death by
comorbidity status among colorectal cancer patients in Spain in
2011 (nZ 1,061, 171 deaths at 6 months and 246 deaths at 1 year).
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risk at 1 year for any of the top 10 most frequent mul-
timorbidity patterns except for only those patients with
CHF and rheumatologic disease in combination with
diabetes. For instance, patients with CHF þ diabetes
had approximately two times excess mortality risk than
patients with no comorbidities or any other different
comorbidity pattern (HR, 1.68; 95% CI: 1.07e2.65) and
those with rheumatologic disease plus diabetes had two
times excess mortality risk (HR, 2.23; 95% CI:
1.23e4.07). Supplementary Fig. S1 shows the cumula-
tive incidences of death for the 10 most frequent mul-
timorbidity patterns.
In sensitivity analysis, the excess mortality HR for the
fully adjusted model 4 restricted to stage IeIII patients
receiving surgery plus all stage IV patients was consistent
with the unrestricted model but a slight reduction in the


























Fig. 2. Short-term cumulative incidences of death by comorbidity
status, adjusted for age, sex, cancer stage and treatment, among
colorectal cancer patients in Spain in 2011 (n Z 1,061, 171 deaths
at 6 months and 246 deaths at 1 year).HR for the unrestricted modelZ 1.23, 95% CI: 0.84e1.79
vs. 1.21, 95% CI: 0.82e1.78 for the unrestricted, and
multimorbidity HR for the unrestricted Z 1.54, 95% CI:
1.08e2.20 vs. 1.43, 95% CI: 1.00e2.07 for the restricted
model). Furthermore, there was evidence of an interaction
between comorbidities with patients’ age and tumour
stage. Table 4 shows the stratum-specific adjustedHRs for
comorbidities and multimorbidity by cancer stage (IeII,
III and IV) and the combined linearmultiplicative effect of
comorbidities with cancer stage and patient’s age. The
association of comorbidities and multimorbidity was
stronger in early-stage tumours (IeII), and there was evi-
dence of a higher risk of short-term mortality at 1 year for
only patients with multimorbidity at stages IeII (i.e.
stratum-specific HR Z 3.83, 95% CI:1.58e9.28) (Table
4A). The combined linear multiplicative effect of comor-
bidities and cancer stage showed that patients with both
multimorbidity and tumour stage IV had ten times higher
excess mortality risk than those patients without comor-
bidity and tumour stage IeII. Furthermore, CRC patients
with multimorbidity and aged 70 years showed three
times higher excess mortality risk than those patients
without comorbidity and tumour stage IeII (Table 4B).4. Discussion
We found that multimorbidity was a strong independent
predictor of short-term mortality among CRC patients
in Spain. However, after adjusting for age, sex, cancer
stage at diagnosis and treatment, no significant associ-
ation was found between increased short-term mortality
at 1 year and having just one comorbidity. Our results
are consistent with previous evidence showing that the
impact of multimorbidity on short-term mortality is
particularly strong in early-stage tumours and older
patients [20] and the findings of a Japanese study with
2,007 participants [21]. They found that age and
comorbidities worsened the overall survival of CRC
patients who underwent curative surgery. However,
patients aged 75 years were undertreated regardless of
cancer stage despite the possibility of overall survival
improvement by adjuvant therapy. Quintana et al. [22]
found that a Charlson comorbidity index of 4 and an
age of >75 years were predictors of 1-year mortality.
More recently, a meta-analysis found that CRC patients
with mild/moderate and severe comorbidities had a
higher 30-day mortality risk than those without
comorbidities (odds ratio, 1.7, 95% CI: 1.26e2.31) [23].
However, previous studies have not explored the impact
of different multimorbidity patterns, and most of them
based multimorbidity patterns on a nonecancer-specific
comorbidity score.
We found that among patients with multimorbidity,
diabetes was the most prevalent comorbidity. Diabetes
has been shown as the most prevalent comorbidity
among CRC patients [24]. A recent meta-analysis of
Table 4
Cancer stage stratum-specific adjusted short-term excess mortality hazard ratios (A) and multiplicative effect of multimorbidity/comorbidity with
cancer stage and age on short-term mortality (1 year) (B) among colorectal cancer patients in Spain, 2011 (n Z 970 and 246 deaths at 1 year).
A: Stratum-specific adjusteda HRs for cancer stage







HR (95%CI) HR (95%CI) HR (95%CI)
No comorbidity Ref. Ref. Ref.
One comorbidity 2.10 (0.79e5.55) 0.73 (0.25e2.19) 0.96 (0.60e1.51)
Multimorbidity 3.83 (1.58e9.28) 1.40 (0.55e3.58) 1.33 (0.85e2.10)
B: Comorbidity combined multiplicative adjustedb effects, n [ 1,061
Comorbidity status Tumour stage
TNM I-II TNM III TNM IV
HR (95%CI) HR (95%CI) HR (95%CI)
No comorbidity Ref. 1.71 (1.07e2.74) 6.50 (4.27e9.90)
One comorbidity 1.24 (0.85e1.81) 2.13 (1.17e3.88) 8.09 (4.61e4.20)
Multimorbidity 1.63 (1.15e2.32) 2.80 (1.57e4.99) 10.63 (6.07e18.60)
Age at diagnosis in years
<55 55e69 70
HR (95%CI) HR (95%CI) HR (95%CI)
No comorbidity Ref. 1.39 (0.69e2.80) 1.99 (1.01e3.92)
One comorbidity 1.25 (0.86e1.82) 1.74 (0.81e3.75) 2.49 (1.20e5.16)
Multimorbidity 1.67 (1.17e2.37) 2.33 (1.09e4.96) 3.33 (1.64e6.74)
Missing values: TNM stage, n(%) Z 60(5.6%), comorbidities, n (%) Z 23(2.2%), type of surgery, n(%) Z 27(2.4%) and chemotherapy,
n(%) Z 22(2.0%).
a Adjusted for age, sex and cancer treatment.
b Adjusted for sex, cancer stage and treatment.
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shorter 5-year overall survival than those without dia-
betes [25]. However, our findings are more specific as we
found that it was not only diabetes that was responsible
for the higher excess mortality risk among CRC patients
but also the combination of diabetes with CHF and
rheumatologic disease. Furthermore, our study shows a
clear dose response effect of comorbidities on CRC
short-term mortality.
Multimorbidity is highly prevalent among the elderly.
Over 60% of cancer cases are diagnosed after 65 years of
age, with 67% of cancer deaths occurring in this age
group [26]. The elderly have less resistance and more
prolonged exposure to carcinogens, a decline in immune
functioning, an alteration in anti-tumour defence
mechanisms, decreased DNA repair, defects in tumour-
suppressor genes and differences in biological behav-
iour, including angiogenesis. These natural frailties and
the increased prevalence of multimorbidity might
detrimentally affect their treatment and survival out-
comes [27]. The elderly are less likely to receive optimal
cancer treatment [28].
Despite the high prevalence of multimorbidity among
cancer patients, the guidelines and delivery of cancer
care generally focus on single-disease management
[29,30]. However, effective management of comorbid
conditions is important in optimizing the patient’shealth status [31], and decisions regarding cancer treat-
ment among the elderly cancer patients require careful
consideration of comorbidities and multimorbidity
[9,32,33]. Furthermore, postoperative complications
occur more frequently in patients with comorbidities
and multimorbidity [10,34], and certain comorbid con-
ditions have been linked to adverse outcomes following
surgery for cancer [9,35]. For instance, cancer patients
with solid tumours and multimorbidity receiving surgery
had a reduced immediate postoperative survival and an
increased short-term mortality in the first 6 months after
surgery [36]. Therefore, cancer research should address
multimorbidity minimizing the occurrence of treatment-
related complications.
Cancer control and treatment research should
address multimorbidity, particularly in the elderly [37].
Considering the increased multimorbidity prevalence in
older age groups and the poorer short-term survival in
these age groups as shown in this study, healthcare
professionals need to be vigilant for common comor-
bidities when providing medical care to patients because
of the tendency toward poor tolerance to cancer treat-
ment and occurrence of complications related to the
interaction between age-related decline in physiological
reserves and comorbidities [27]. Thus, improved coor-
dination and communication between different health-
care disciplines are crucial to optimizing the
M.A. Luque-Fernandez et al. / European Journal of Cancer 129 (2020) 4e1412management of pre-existing comorbid conditions for the
best cancer survival outcomes and minimizing the
occurrence of treatment-related complications among
the elderly.
Social inequalities also play a role in CRC survival.
Fowler et al. analysed the socioeconomic status of
69,769 English patients and concluded that the proba-
bility of death rose with increasing deprivation, even
after accounting for the main prognostic factors [38].
Our study design is limited in that it does not allow
adjustment for socioeconomic status; thus, further
research is necessary to explore the impact of socio-
economic status on short-term CRC survival in Spain.
Moreover, including only one calendar year of CRC
incident cases from only two population-based cancer
registries might have limited the external validity of our
findings. This restriction was due to data availability
and the assessment of patients’ follow-up. However, our
findings are consistent with current evidence, and most
importantly, they are unique and relevant for public
health policy as to our knowledge, this is the first study
to investigate the association between multimorbidity
and short-term mortality among CRC patients in Spain.
The treatment of CRC, especially for stage III and IV,
influences the survival outcomes of CRC patients. For
stage III patients, adjuvant treatment using chemo-
therapy is standard (unless very old and frail), and for
stage IV, the treatment intent is most likely palliative,
and mainstay of treatment is generally chemotherapy
instead of surgery [39,40]. Thus, the inclusion of the
treatment information in our study is a strength. How-
ever, in multivariate analysis given the small number of
events we had to dichotomize both variables limiting the
scope of the available information. Finally, we per-
formed a complete case analysis given the reduced per-
centage of missing values (i.e. 2.2% for comorbidities)
and caution is required in the interpretation of the un-
adjusted and adjusted HRs due to small numbers,
particularly for some categories of age and cancer stage
and the stratum specific HRs in the sensitivity analysis.
The most commonly used comorbidity index in
population-based cancer epidemiology is the Charlson’s
Comorbidity Index [41]. However, controversies exist
regarding the application of different comorbidity scores
and their weighting algorithms. The CCI has been
criticised for using weights that are not cancer specific
[32], it includes some conditions that have not been
shown to have an impact on survival among patients
with cancer, and it assumes that the impact of multiple
conditions is additive on a relative risk scale [42,43].
However, the RCS-modified Charlson score is a simple
cancer-specific multimorbidity indicator that shifts the
focus from a single disease paradigm to one where the
causes and effects of multiple combined conditions are
explored. Using the RCS-modified Charlson comor-
bidity score, originally used to evaluate mortality risk
during surgery, is another strength of this study. Thescore uses 12 comorbidities considered equally impor-
tant and identified among CRC patients [15] and is thus
cancer specific. Various other scoring systems for
measuring comorbidity are not cancer-specific or focus
only on single comorbid conditions in isolation
[41,44,45]. However, there has been no agreed gold
standard to measure comorbidity in cancer patients [46].
The validation of the RCS-modified Charlson score
showed moderate to very good discrimination. There is
evidence showing that the RCS-modified Charlson score
improved the performance of predictive models for
short-term outcomes (in-hospital mortality) as well as 1-
year mortality (C-statistic: 0.87) [15]. CRC is a disease
related with aging, and multimorbidity is often attrib-
uted to the aging process. Thus, the occurrence of
multimorbidity is more realistically conceptualised using
a multimorbidity score. However, in comparison to co-
morbidity, the term ‘multimorbidity’ indicates that no
single condition holds priority over any of the co-
occurring conditions, and it might be a limitation.
Therefore, we provided the information on the individ-
ual comorbidities integrating the most common multi-
morbidity patterns identified among CRC patients in
our study [47].
Tailored risk-assessment tools that consider the ef-
fects of multimorbidity and its treatment are needed to
support clinicians when evaluating the possibility of
multimorbidity in cancer patients. Currently, available
tools for this purpose are based on generic algorithms
[48], although approaches that are more sophisticated
could take advantage of emerging technologies such as
artificial intelligence [48].
In conclusion, we found that multimorbidity was a
strong independent predictor of increased short-term
excess mortality risk at 6 months and 1 year among
CRC patients in Spain, and the most commonly iden-
tified multimorbidity patterns showed an excess short-
term mortality risk. Our findings might help identify
patients at a higher risk for poorer cancer and treatment
outcomes. Early detection and risk-reduction strategies
may reduce the adverse impact of some of these adverse
effects on patients.
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